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Heart failure impairs cerebral oxygenation
during exercise in patients with COPD
To the Editor:
Impaired systemic oxygen delivery, particularly during exertion, is the key pathophysiological feature shared
by chronic obstructive pulmonary disease (COPD) and heart failure with reduced left ventricular ejection
fraction (HFrEF). Unfortunately, COPD and HFrEF frequently coexist not only because of their high
individual prevalence but also due to common risk factors, including cigarette smoking, advanced age,
oxidative stress and systemic inflammation [1].
It is expected that any reduction in the rate of oxygen transfer due to COPD and/or HFrEF would be
particularly deleterious to tissues heavily dependent upon constant oxygen flow, such as the central nervous
system (as reviewed in [2]). Exercise cerebral oxygenation (Cox) (as noninvasively determined by near-
infrared spectroscopy) depends upon the dynamic balance between the instantaneous rate of oxygen
delivery and oxygen utilisation [3]. KOIKE et al. [4], for instance, reported that congestive heart failure
(CHF) HFrEF was associated with appreciable decreases in COx during exertion. Our laboratory found that
exercise COx might be impaired in some patients with more advanced COPD, even if not overtly
hypoxaemic [5]. Moreover, improvement in cardiac output with noninvasive ventilation (under the same
arterial oxygen content) had positive effects on COx in COPD [6]. These data suggest that reduced cerebral
blood flow might be mechanistically linked to impaired exercise COx in some patients with moderate-to-
severe COPD. It is conceivable that the presence of HFrEF would further deteriorate this scenario by adding
components of dysfunctional cerebral autoregulation, lower cardiac output and hypocapnia-induced
vasoconstriction [4]. The compound effects of HFrEF plus COPD on COx and its relationship with exercise
tolerance, however, remain unknown. In order to address these issues, we simultaneously assessed COx,
systemic haemodynamics and gas exchange during progressive exercise in COPD patients presenting or not
with HFrEF as a comorbidity.
33 males with stable, nonhypercapnic (arterial carbon dioxide tension ,45 mmHg at rest) COPD with a
long history of smoking (.20 pack-years), breathlessness in daily life (modified Medical Research Council
(MRC) scale scores .2) and moderate-to-severe airflow obstruction comprised the study group. Patients
from the COPD+HFrEF group (n518) presented with left ventricular ejection fraction by Doppler
echocardiography ,40% and well-established diagnosis of CHF (dyspnoea on exertion, elevated jugular
venous pressure, cardiomegaly, peripheral oedema and pulmonary crepitations) due to underlying
ischaemic heart disease. All patients were under standard contemporary therapy for HFrEF. 15 patients
from the COPD clinic without clinical, echocardiographic and laboratorial evidence of CHF (n515) were
matched by age and MRC grade (table 1). The main exclusion criteria included long-term ambulatory
oxygen therapy, severe pulmonary hypertension (mean pulmonary artery pressure o40 mm Hg), anaemia
(haemoglobin concentration ,13 g%), and recent exacerbation (within 1 month). After providing
informed consent (as approved by the local medical ethics committee), patients underwent a ramp-
incremental cardiopulmonary exercise test with assessment of arterialised carbon dioxide tension (PCO2).
Changes from rest (D) in pre-frontal COx (oxyhaemoglobin concentration ([HbO2])) were measured by
near infrared spectroscopy (NIRO 200TM; Hamamatsu Photonics KK, Hamamatsu, Japan) and cardiac
output by transthoracic cardioimpedance (PhysioFlow PF-5TM; Manatec Biomedical, Paris, France) [7].
Based on a pooled analysis of our previous data in normal older subjects and patients with COPD [5, 6],
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DCOx increases ,1.10 fold and/or any reduction were assumed to indicate a physiologically inadequate
response. One-way ANOVA with repeated measures was used to identify statistically significant between-
group differences across different time-points. Pearson’s correlation analysis was used to assess association
between variables. For all tests, a statistical significance of 0.05 was used.
We found that COPD+HFrEF patients had lower maximal exercise capacity than their counterparts with
COPD. In addition, the former group showed increased ventilatory response to metabolic demand, which
was associated with greater oxygen saturation (fig. 1b) but lower arterialised and end-tidal PCO2 than their
counterparts with COPD (table 1). COPD+HFrEF patients showed blunted haemodynamic responses
(cardiac output and mean arterial pressure) during submaximal (fig. 1c and d) and maximal exercise
(table 1). Changes in DCOx with exercise progression were also reduced in the COPD+HFrEF group
(fig. 1a). In fact, whereas DCOx increased in 11 (73.3%) out of 15 patients with COPD it remained stable or
even decreased in 14 (77.7%) out of 18 patients with COPD+HFrEF. DCOx was particularly impaired in
patients in whom mean systemic arterial pressure remained stable or decreased (p,0.05). Interestingly,
TABLE 1 Resting and exercise characteristics in chronic obstructive pulmonary disease
(COPD) patients with or without heart failure with reduced ejection fraction (HFrEF) as a
comorbidity
COPD+HFrEF COPD
Subjects n 18 15
General characteristics
Age years 67¡7 65¡8
Body mass index kg?m-2 25.0¡4.1 24.2¡3.9
Smoking pack-years 51.3¡30.1 45.5¡26.5
Left ventricular ejection fraction % 35.3¡7.6* 64.9¡3.8
Lung function
FEV1
L 1.70¡0.52 1.31¡0.64
% pred 64.1¡18.3* 46.3¡15.6
FEV1/FVC 63.1¡9.3* 41.7¡9.4
TLC % pred 83.5¡22.5* 109.3¡12.6
TLCO % pred 51.4¡14.2 56.9¡16.1
PaO2 mmHg 65.3¡7.0 61.9¡9.2
PaCO2 mmHg 34.1¡3.3 37.6¡6.6
Exercise
Peak work rate W 53¡24 65¡24
Peak oxygen uptake
L?min-1 1.03¡0.32* 1.21¡0.30
% pred 52¡12* 64¡14
Cardiac output L?min-1
Absolute 8.9¡2.6* 10.9¡3.0
D from rest 3.1¡1.8* 4.3¡1.5
Mean arterial pressure mmHg
Absolute 99¡20* 120¡14
D from rest 8¡5* 22¡7
DV9E/DV9CO2 38.7¡9.3* 28.8¡7.2
PETCO2 mmHg 31.8¡5.8* 37.6¡6.1
Arterialised PCO2 mmHg
Absolute 32.4¡5.2* 38.1¡6.7
D from rest 0.6¡2.3* 4.7¡2.1
SpO2 %
Absolute 93¡3* 90¡6
D from rest 0¡3* -4¡3
Data are presented as mean¡SD, unless otherwise stated. FEV1: forced expiratory volume in 1 s; % pred: %
predicted; FVC: forced vital capacity; TLC: total lung capacity; TLCO: transfer factor of the lung for carbon
monoxide; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; D: change; V9E: minute
ventilation; V9CO2: carbon dioxide output; PETCO2: end-tidal carbon dioxide tension; PCO2: carbon dioxide tension;
SpO2: arterial oxygen saturation measured by pulse oximetry. *: p,0.05.
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peak work rate was related to submaximal DCOx (area under the curve to an iso-work rate of 40 W) only in
the COPD+HFrEF group (r50.67, p,0.01).
Lower arterial oxygen content could be a potential explanation for reduced COx in COPD+ HFrEF, as CHF
per se can reduce lung diffusing capacity, worsen ventilation/perfusion mismatch and decrease mixed
oxygen venous pressure. However, we found the opposite, as these patients showed better-preserved arterial
oxygenation than their counterparts with COPD alone. Lower PCO2 and impaired cerebral perfusion
pressure (either due to low mean arterial pressure and/or cardiac output) emerge as the obvious culprits.
Indeed, mean arterial pressure, a major determinant of cerebral blood flow [8], was reduced throughout the
exercise tests and related to COx in COPD+HFrEF. Slight impairments in mean arterial pressure might
reduce cerebral blood flow, particularly in the presence of impaired autoregulation and excessive
sympathetic drive [3, 8]. There is also some evidence that decreased cardiac output may impair exercise
COx, independent of mean arterial pressure [8]. All patients were under cardioselective b-blocker therapy,
and diminished heart rate response was the main mechanism for a reduced exercise cardiac output. This
suggests a link between pharmacologically induced decrements in exercise chronotropic response and low
exercise COx.
What is the practical relevance of these findings? Our data suggest that pharmacological treatment of HFrEF
should take into consideration that the pre-frontal cortex is particularly sensitive to pressure perfusion
impairments in patients with COPD. Impaired exercise DCOx is an independent prognostic factor in
patients with cardiovascular disease and a predictor of cerebral ischaemic events [3]. It is noteworthy that
stroke is more frequent in COPD patients when HFrEF coexists [9]. It is also conceivable that COx deficits
reported herein would be observed in other clinical scenarios, such as acute exacerbations or diuretic-
induced hypovolaemia. Derangements in DCOx may also reduce motor output (central fatigue) and
contribute to early exercise cessation [2]. In fact, DCOx was related to peak exercise capacity only in the
COPD+HFrEF group. If future studies establish a cause–effect relationship, interventions aimed at
improving cerebral blood flow during exertion might prove useful ergogenic aids for these patients.
Limitations of this study include its small sample size, heterogeneity of COPD severity, noninvasive
determination of cardiac output, lack of cognition and cerebral blood flow measurements. It should be
recognised, however, that D[HbO2] is not only a useful indicator of changes in intracerebral perfusion but
also relates closely with cognition (reviewed in [10]). The COPD+HFrEF group showed less airflow
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FIGURE 1 Changes in a) pre-frontal cerebral oxygenation (DCOx), b) arterial oxygen saturation measured by pulse oximetry (SpO2), c) cardiac output (QT) and
d) mean arterial pressure (MAP) as a function of exercise intensity in chronic obstructive pulmonary disease (COPD) patients with or without heart failure with
reduced ejection fraction (HFrEF) as comorbidity. Data are presented as mean¡SE. *: p,0.05 for between-group comparisons; #: p,0.05 for intragroup
comparisons against unloaded cycling.
1425
obstruction than their counterparts with COPD. Thus, we might have underestimated the deleterious effects
of HFrEF on cerebral haemodynamics in COPD. It also remains to be demonstrated whether impairment in
COx in COPD+HFrEF is out of proportion to HFrEF alone.
In conclusion, this study provides novel evidence that the coexistence of HFrEF impairs cerebral
oxygenation (and conceivably cerebral blood flow) during exercise in moderate-to-severe COPD.
Additional studies are warranted to address whether this might be contributory to exercise intolerance
and its clinical implications for prognosis, treatment and rehabilitation of the fast-growing population of
patients with the COPD+HFrEF overlap.
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